New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - amlodipine besilate 14mg equivalent to to 10 mg amlodipine;   - tablet - 10 mg - active: amlodipine besilate 14mg equivalent to to 10 mg amlodipine   excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - apo-amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent, or an angiotensin-converting enzyme inhibitor. apo-amlodipine is indicated for the first line treatment of myocardial ischaemia, whether due to fixed obstruction (stable angina) and/or vasospasm/vasoconstriction (prinzmetal's or variant angina) of coronary vasculature. amlodipine may be used where the clinical presentation suggests a possible vasospastic/vasoconstrictive component but where vasospasm/vasoconstriction has not been confirmed. apo-amlodipine may be used alone as monotherapy, or in combination with other antianginal drugs in patients with angina that is refractory to nitrates and/or beta blockers.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - amlodipine besilate 3.5mg equivalent to 2.5 mg amlodipine;   - tablet - 2.5 mg - active: amlodipine besilate 3.5mg equivalent to 2.5 mg amlodipine   excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - apo-amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent, or an angiotensin-converting enzyme inhibitor. apo-amlodipine is indicated for the first line treatment of myocardial ischaemia, whether due to fixed obstruction (stable angina) and/or vasospasm/vasoconstriction (prinzmetal's or variant angina) of coronary vasculature. amlodipine may be used where the clinical presentation suggests a possible vasospastic/vasoconstrictive component but where vasospasm/vasoconstriction has not been confirmed. apo-amlodipine may be used alone as monotherapy, or in combination with other antianginal drugs in patients with angina that is refractory to nitrates and/or beta blockers.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - amlodipine besilate 7mg equivalent to to 5 mg amlodipine;   - tablet - 5 mg - active: amlodipine besilate 7mg equivalent to to 5 mg amlodipine   excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - apo-amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent, or an angiotensin-converting enzyme inhibitor. apo-amlodipine is indicated for the first line treatment of myocardial ischaemia, whether due to fixed obstruction (stable angina) and/or vasospasm/vasoconstriction (prinzmetal's or variant angina) of coronary vasculature. amlodipine may be used where the clinical presentation suggests a possible vasospastic/vasoconstrictive component but where vasospasm/vasoconstriction has not been confirmed. apo-amlodipine may be used alone as monotherapy, or in combination with other antianginal drugs in patients with angina that is refractory to nitrates and/or beta blockers.

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - amlodipine besilate,atorvastatin calcium propylene glycol solvate -

United States - English - NLM (National Library of Medicine)

apotex corp. - atorvastatin calcium propylene glycol solvate (unii: yrz789owmi) (atorvastatin - unii:a0jwa85v8f) - atorvastatin 10 mg - atorvastatin calcium tablets are indicated: - to reduce the risk of: myocardial infarction (mi), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (chd) but without clinically evident chd mi and stroke in adults with type 2 diabetes mellitus with multiple risk factors for chd but without clinically evident chd non-fatal mi, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident chd - myocardial infarction (mi), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (chd) but without clinically evident chd - mi and stroke in adults with type 2 diabetes mellitus with multiple risk factors for chd but without clinically evident chd - non-fatal mi, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident chd -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atorvastatin calcium propylene glycol solvate -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atorvastatin calcium propylene glycol solvate -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atorvastatin calcium propylene glycol solvate -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atorvastatin calcium propylene glycol solvate -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - atorvastatin calcium -